Quantum-Si Unveils New Research on Human Cohesin Complexes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy QSI?
Source: Newsfilter
- Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
- Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
- Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
- Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QSI
Wall Street analysts forecast QSI stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.070
Low
1.50
Averages
2.67
High
4.00
Current: 1.070
Low
1.50
Averages
2.67
High
4.00
About QSI
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum-Si to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
- Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
- Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
- Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
See More
Quantum-Si Showcases New Technology at AACR Conference
- Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
- Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
- Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
- Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
See More
Quantum-Si Unveils New Research on Human Cohesin Complexes
- Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
- Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
- Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
- Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
See More
Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
- Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
- Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
See More
Quantum-Si's Proteus Prototype Surpasses Platinum Performance
- Successful Sample Sequencing: Quantum-Si has successfully completed the sequencing of multiple samples on its Proteus prototype system, demonstrating that it exceeds Platinum Pro performance across all relevant metrics, marking a significant milestone in the development of this new platform.
- Significant Technical Advantages: The Proteus prototype system shows substantial improvements in amino acid coverage, read lengths, peptide identification, and sequencing output, even when normalized for the difference in nanowell counts compared to the Platinum Pro chip, highlighting its superior performance.
- Strong Customer Demand: Several customers have expressed interest in providing samples for sequencing on the Proteus prototype, and Quantum-Si is closely collaborating with manufacturing partners to increase the delivery rate of integrated Proteus systems to meet internal R&D demands and offer market sample testing capabilities.
- Optimistic Future Outlook: Quantum-Si expects sequencing performance to continue improving as the Proteus system is further optimized, with plans to provide more updates on this program during the next earnings call, reflecting the company's confidence in future developments.
See More
Quantum-Si Launches Multi-City Roadshow for Proteus Awareness
- Roadshow Launch: Quantum-Si has announced the start of a multi-city roadshow aimed at increasing market awareness of its Proteus platform and protein sequencing applications, with the first event scheduled for April 7, 2026, in Seattle, followed by stops in Washington D.C. and Houston, which is expected to significantly expand its potential customer base.
- Customer Engagement: The roadshow will feature presentations from existing customers showcasing applications of protein sequencing using the company's first-generation Platinum® Pro instrument, which not only helps build customer trust but also creates strong market demand for the upcoming Proteus platform.
- Market Education: Through this roadshow, Quantum-Si aims to accelerate market education and enhance awareness of Proteus, which is expected to exceed the capabilities of Platinum Pro, thereby positioning the company more favorably in the competitive protein analysis market.
- Strategic Importance: CEO Jeff Hawkins stated that this roadshow is a crucial part of the company's pre-launch strategy, designed to rapidly build a funnel of prospective customers through the effectiveness of its direct sales team, laying the groundwork for the commercialization of Proteus.
See More
Quantum-Si to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
- Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
- Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
- Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
See More
Quantum-Si Showcases New Technology at AACR Conference
- Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
- Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
- Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
- Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
See More
Quantum-Si Unveils New Research on Human Cohesin Complexes
- Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
- Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
- Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
- Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
See More
Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
- Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
- Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
See More
Quantum-Si's Proteus Prototype Surpasses Platinum Performance
- Successful Sample Sequencing: Quantum-Si has successfully completed the sequencing of multiple samples on its Proteus prototype system, demonstrating that it exceeds Platinum Pro performance across all relevant metrics, marking a significant milestone in the development of this new platform.
- Significant Technical Advantages: The Proteus prototype system shows substantial improvements in amino acid coverage, read lengths, peptide identification, and sequencing output, even when normalized for the difference in nanowell counts compared to the Platinum Pro chip, highlighting its superior performance.
- Strong Customer Demand: Several customers have expressed interest in providing samples for sequencing on the Proteus prototype, and Quantum-Si is closely collaborating with manufacturing partners to increase the delivery rate of integrated Proteus systems to meet internal R&D demands and offer market sample testing capabilities.
- Optimistic Future Outlook: Quantum-Si expects sequencing performance to continue improving as the Proteus system is further optimized, with plans to provide more updates on this program during the next earnings call, reflecting the company's confidence in future developments.
See More
Quantum-Si Launches Multi-City Roadshow for Proteus Awareness
- Roadshow Launch: Quantum-Si has announced the start of a multi-city roadshow aimed at increasing market awareness of its Proteus platform and protein sequencing applications, with the first event scheduled for April 7, 2026, in Seattle, followed by stops in Washington D.C. and Houston, which is expected to significantly expand its potential customer base.
- Customer Engagement: The roadshow will feature presentations from existing customers showcasing applications of protein sequencing using the company's first-generation Platinum® Pro instrument, which not only helps build customer trust but also creates strong market demand for the upcoming Proteus platform.
- Market Education: Through this roadshow, Quantum-Si aims to accelerate market education and enhance awareness of Proteus, which is expected to exceed the capabilities of Platinum Pro, thereby positioning the company more favorably in the competitive protein analysis market.
- Strategic Importance: CEO Jeff Hawkins stated that this roadshow is a crucial part of the company's pre-launch strategy, designed to rapidly build a funnel of prospective customers through the effectiveness of its direct sales team, laying the groundwork for the commercialization of Proteus.
See More
